Keyword: Humira

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.

Biogen is putting down $100 million upfront for copycats to Roche's Lucentis, Regeneron's Eylea and new rights for anti-TNF drugs in China.

Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly. 

AbbVie’s Skyrizi joins pharma TV spending sibling drug Humira in October list of top outlays.

AbbVie, which markets psoriasis fighters Humira and Skyrizi, launched a new digital awareness push aimed at helping patients speak up for better care.

AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?

Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.

For the second month in a row, AbbVie’s Humira, Gilead Sciences' Truvada and Allergan’s Botox topped pharma TV spending in that order.